Yumanity Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $20.52 million
- Book Value:
- Revenue TTM:
- $4.84 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Yumanity Therapeutics Inc had its IPO on 2016-02-11 under the ticker symbol YMTX.
The company operates in the Healthcare sector and Biotechnology industry. Yumanity Therapeutics Inc has a staff strength of 40 employees.
Shares of Yumanity Therapeutics Inc opened at $1.63 at the start of the last trading session i.e. 2023-06-03.
The stocks traded within a range of $1.4 - $1.89, and closed at $1.89.
This is a +8.62% increase from the previous day's closing price.
A total volume of 0 shares were traded at the close of the day’s session.
In the last one week, shares of Yumanity Therapeutics Inc have increased by +400%.
Yumanity Therapeutics Inc's Key Ratios
Yumanity Therapeutics Inc has a market cap of $20.52 million, indicating a price to book ratio of 3.3307 and a price to sales ratio of 3.9005.
In the last 12-months Yumanity Therapeutics Inc’s revenue was $4.84 million with a gross profit of $-18366000 and an EBITDA of $-27043000. The EBITDA ratio measures Yumanity Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Yumanity Therapeutics Inc’s operating margin was -563% while its return on assets stood at -42.93% with a return of equity of -168.66%.
In Q3, Yumanity Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 14.3%.
Yumanity Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-4.241 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Yumanity Therapeutics Inc’s profitability.
Yumanity Therapeutics Inc stock is trading at a EV to sales ratio of 2.0704 and a EV to EBITDA ratio of -0.3219. Its price to sales ratio in the trailing 12-months stood at 3.9005.
Yumanity Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $9.58 million
- Total Liabilities
- $4.10 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Yumanity Therapeutics Inc ended 2023 with $9.58 million in total assets and $0 in total liabilities. Its intangible assets were valued at $9.58 million while shareholder equity stood at $5.48 million.
Yumanity Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $4.10 million in other current liabilities, 11000.00 in common stock, $-208902000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $8.42 million and cash and short-term investments were $8.42 million. The company’s total short-term debt was $204,000 while long-term debt stood at $0.
Yumanity Therapeutics Inc’s total current assets stands at $9.08 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $0.00 compared to accounts payable of $1.69 million and inventory worth $0.
In 2023, Yumanity Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $53000.
Comparatively, Yumanity Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Yumanity Therapeutics Inc stock is currently trading at $1.89 per share. It touched a 52-week high of $2.2194 and a 52-week low of $2.2194. Analysts tracking the stock have a 12-month average target price of $27.6667.
Its 50-day moving average was $1.67 and 200-day moving average was $1.55 The short ratio stood at 1.24 indicating a short percent outstanding of 0%.
Around 1961.7% of the company’s stock are held by insiders while 2257% are held by institutions.
Frequently Asked Questions About Yumanity Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson’s disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.